Dergiler / Turkish Journal of Medical Sciences / 2016 / Cilt: 46 - Sayı: 6

The effect of methylprednisolone treatment on fibrinolysis, the coagulation system, and blood loss in cardiac surgery

Sayfa
1645–1654
Yayın Tarihi
2022-11-05
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: Methylprednisolone at a dose of 15 mg/kg reduced bleeding, probably by increasing CD62P after heparin neutralization, which can activate platelet activation in favor of better hemostasis.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/aim: The purpose of this study was to examine steroid pretreatment in order to decrease postoperative coagulopathy disorders and bleeding.
📊
Temel Bulgular & Veri:The platelet response to agonists, D-dimer concentration, tissue plasminogen activator (tPA), plasminogen activator inhibitor (PAI-1) antigens, and platelet receptors CD42b, CD62P, and CD41a were evaluated.
💡
Sonuç & Katkı:Conclusion: Methylprednisolone at a dose of 15 mg/kg reduced bleeding, probably by increasing CD62P after heparin neutralization, which can activate platelet activation in favor of better hemostasis.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Background/aim: The purpose of this study was to examine steroid pretreatment in order to decrease postoperative coagulopathy disorders and bleeding. Materials and methods: In this randomized double-blinded study, the efficacy of low versus high doses of methylprednisolone on the coagulation system and postoperative bleeding was compared in patients who were undergoing cardiac surgery with cardiopulmonary bypass (CPB). The platelet response to agonists, D-dimer concentration, tissue plasminogen activator (tPA), plasminogen activator inhibitor (PAI-1) antigens, and platelet receptors CD42b, CD62P, and CD41a were evaluated. Results: The platelet response to agonists was reduced. The mean concentrations of D-dimer and tPA antigen increased although PAI1 concentration did not show any significant changes following heparin neutralization. Postoperative expression of CD42b showed no changes in comparison with preoperation values in both groups. There was a significant increase in the expression of CD62P with a methylprednisolone dose of 15 mg/kg, while there was just a slight increase with a dose of 5 mg/kg. CD41a, as a fibrinogen receptor, was increased significantly after CPB in both groups. Significant data were shown in decreasing blood loss with a high dose of methylprednisolone. Conclusion: Methylprednisolone at a dose of 15 mg/kg reduced bleeding, probably by increasing CD62P after heparin neutralization, which can activate platelet activation in favor of better hemostasis.

🔖

Bu Makaleye Atıf Yap

EBRAHIMI, L., KHEIRANDISH, M., FOROUGHI, M. (2022). The effect of methylprednisolone treatment on fibrinolysis, the coagulation system, and blood loss in cardiac surgery. Turkish Journal of Medical Sciences, Cilt: 46 - Sayı: 6, 1645–1654. https://ajindex.com/articles/610845

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Kojima T, Gando S, Morimoto Y. Systematic elucidation of effects of tranexamic acid on fibrinolysis and bleeding during and after cardiopulmonary bypass surgery. Thromb Res 2001; 104: 301-307
  2. Day JRS, Taylor KM. The systemic inflammatory response syndrome and cardiopulmonary bypass. Int J Surg 2005; 3: 129-140
  3. Despotis G, Eby C, Lublin DM. A review of transfusion risks and optimal management of perioperative bleeding with cardiac surgery. Transfusion 2008; 48: 2S-30S
  4. Robinson KL, Marasco SF. Practical management of anticoagulation, bleeding and blood product support for cardiac surgery. Heart Lung Circ 2001; 10: 142-153
  5. Boyle EM, Verrier ED, Spiess BD. Endothelial cell injury in cardiovascular surgery: the procoagulant response. Ann Thorac Surg 1996; 62: 1549-1557
  6. Mahdi AM, Webster NR. Perioperative systemic haemostatic agents. Brit J Anaesth 2004; 93: 842-858
  7. Ray MJ, Marsh NA, Just SJ, Perrin EJ, O’Brien MF, Hawson GA. Preoperative platelet dysfunction increases the benefit of aprotinin in cardiopulmonary bypass. Ann Thorac Surg 1997; 63: 57-63
  8. Santamaria A, Mateo J, Muñíz-Díaz E, Oliver A, Murillo J, Litvan H, Souto JC, Fontcuberta J. Platelet function during cardiopulmonary bypass not changed by two different doses of aprotinin. Haematologica 2000; 85: 381-385
  9. Pelletier MP, Solymoss S, Lee A. Negative reexploration for cardiac postoperative bleeding: can it be therapeutic? Ann Thorac Surg 1998; 65: 999-1002
  10. Pagano D, Howell NJ, Freemantle N, Cunningham D, Bonser RS, Graham TR, Mascaro J, Rooney SJ, Wilson IC, Cramb R et al. Bleeding in cardiac surgery: the use of aprotinin does not affect survival. J Thorac Cardiovasc Surg 2008; 135: 495-502
  11. Valen G, Eriksson E, Risberg B, Vaage J. Fibrinolysis during cardiac surgery. Release of tissue plasminogen activator in arterial and coronary sinus blood. Eur J Cardiothorac Surg 1994; 8: 324-330
  12. George JN, Pickett EB, Saucerman S, McEver RP, Kunicki TJ, Kieffer N, Newman PJ. Platelet surface glycoprotein. Studies on resting and activated platelet and platelet membrane microparticles in normal subjects and observations in patients during adult respiratory distress syndrome and cardiac surgery. J Clin Invest 1986; 78: 340-348. 13. van Oeveren W, Kazatchkine MD, Descamps-Latscha B, Maillet F, Fischer E, Carpentier A, Wildevuur CR. Deleterious effects of cardiopulmonary bypass. A prospective study of bubble versus membrane oxygenation. J Thorac Cardiovasc Surg 1985; 89